MARKET

DNTH

DNTH

Dianthus Therapeutics Inc
NASDAQ
39.68
-1.53
-3.71%
After Hours: 39.68 0 0.00% 16:20 01/02 EST
OPEN
41.11
PREV CLOSE
41.21
HIGH
41.53
LOW
38.75
VOLUME
617.39K
TURNOVER
--
52 WEEK HIGH
45.46
52 WEEK LOW
13.37
MARKET CAP
1.70B
P/E (TTM)
-11.3915
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DNTH last week (1222-1226)?
Weekly Report · 12/29/2025 10:08
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047
TipRanks · 12/23/2025 11:05
NANJING LEADS BIOLABS CO LTD: TOP-LINE RESULTS IN HEALTHY VOLUNTEERS ANTICIPATED IN 2H'26
Reuters · 12/23/2025 11:00
LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Reuters · 12/23/2025 11:00
Dianthus Therapeutics Licenses Global Rights to LBL-047 from Leads Biolabs
Reuters · 12/23/2025 11:00
Dianthus Therapeutics Price Target Maintained With a $46.00/Share by Wedbush
Dow Jones · 12/22/2025 13:47
Wedbush Reiterates Outperform on Dianthus Therapeutics, Maintains $46 Price Target
Benzinga · 12/22/2025 13:37
Wedbush Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
TipRanks · 12/22/2025 13:16
More
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Webull offers Dianthus Therapeutics Inc stock information, including NASDAQ: DNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNTH stock methods without spending real money on the virtual paper trading platform.